ADPT
Adaptive Biotechnologies Corporation
Price Chart
Latest Quote
$16.89
-1.19 (-6.58%)
Current Price
| Previous Close | $18.08 |
| Open | $17.99 |
| Day High | $18.29 |
| Day Low | $16.76 |
| Volume | 1,174,726 |
Stock Information
| Shares Outstanding | 160.04M |
| Total Debt | $208.18M |
| Cash Equivalents | $218.33M |
| Revenue | $295.41M |
| Net Income | $-49.68M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $2.70B |
| EPS (TTM) | $-0.32 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.70B |
| Sales | $295.41M |
| Income | $-49.68M |
| Book/sh | $1.35 |
| Cash/sh | $1.36 |
| Employees | 624 |
Financial Ratios
| Quick Ratio | 3.08 |
| Current Ratio | 3.35 |
| Debt/Eq | 92.84 |
Returns & Margins
| ROA | -5.74% |
| ROE | -23.96% |
| Gross Margin | 43.71% |
| Operating Margin | -27.10% |
| Profit Margin | -16.82% |
Ownership
| Insider Ownership | 1.84% |
| Institutional Ownership | 96.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -66.84 |
| P/S | 9.16 |
| P/B | 12.47 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $20.14 |
Technical Indicators
| SMA20 | $14.36 |
| SMA50 | $14.17 |
| SMA200 | $15.26 |
| RSI | 76.46 |
| ATR | 0.9029 |
| Shares Float | 125.30M |
| Short Float | 7.02% |
| Short Ratio | 5.62 |
| Volatility | 2.15 |
| Rel Volume | 1.21 |
Performance History
| Week | +11.55% |
| Month | +17.12% |
| Quarter | +13.73% |
| 6 Months | -1.34% |
| YTD | +6.22% |
| Year | +69.34% |
| 3 Years | +142.82% |
| 5 Years | -55.30% |
| 10 Years | -58.06% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $16.90 | 2,137,185 |
| 2026-06-04 | $18.08 | 4,415,800 |
| 2026-06-03 | $15.99 | 2,236,600 |
| 2026-06-02 | $15.14 | 1,631,600 |
| 2026-06-01 | $15.23 | 1,571,700 |
| 2026-05-29 | $15.15 | 2,293,300 |
| 2026-05-28 | $15.19 | 1,579,100 |
| 2026-05-27 | $13.84 | 2,775,300 |
| 2026-05-26 | $14.13 | 904,500 |
| 2026-05-22 | $13.88 | 1,235,000 |
| 2026-05-21 | $13.87 | 1,075,800 |
| 2026-05-20 | $13.96 | 1,918,800 |
| 2026-05-19 | $12.96 | 1,247,100 |
| 2026-05-18 | $12.71 | 1,593,300 |
| 2026-05-15 | $12.83 | 1,563,600 |
| 2026-05-14 | $13.18 | 1,600,100 |
| 2026-05-13 | $13.13 | 1,285,900 |
| 2026-05-12 | $13.63 | 1,233,400 |
| 2026-05-11 | $13.54 | 1,505,400 |
| 2026-05-08 | $13.81 | 1,522,100 |
| 2026-05-07 | $14.69 | 1,950,100 |
| 2026-05-06 | $14.43 | 4,900,100 |
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
đ° Latest News
How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor
Simply Wall St. âĸ 2026-06-04T11:10:51Z
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
MarketBeat âĸ 2026-06-03T22:04:39Z
Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026
Insider Monkey âĸ 2026-06-03T18:00:01Z
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
Motley Fool âĸ 2026-05-26T20:23:58Z
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance
Simply Wall St. âĸ 2026-05-11T06:07:25Z
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks âĸ 2026-05-05T22:30:02Z
Adaptive Biotechnologies Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-05T22:23:14Z
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-05T22:05:04Z
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.
Motley Fool âĸ 2026-05-04T21:49:27Z
How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions
Simply Wall St. âĸ 2026-05-03T05:10:17Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $55,225,000 | $54,527,000 | $55,021,000 | $38,688,000 |
| Cost Of Revenue | $71,359,000 | $72,080,000 | $75,553,000 | $57,909,000 |
| Total Revenue | $276,976,000 | $178,957,000 | $170,276,000 | $185,308,000 |
| Operating Revenue | $276,976,000 | $178,957,000 | $170,276,000 | $185,308,000 |
| Expenses | ||||
| Interest Expense | $11,778,000 | $11,580,000 | $13,800,000 | $4,238,000 |
| Total Expenses | $334,099,000 | $334,301,000 | $371,882,000 | $385,494,000 |
| Net Non Operating Interest Income Expense | $-2,334,000 | $2,954,000 | $1,731,000 | $-182,000 |
| Interest Expense Non Operating | $11,778,000 | $11,580,000 | $13,800,000 | $4,238,000 |
| Operating Expense | $262,740,000 | $262,221,000 | $296,329,000 | $327,585,000 |
| Selling And Marketing Expense | $94,571,000 | $84,759,000 | $88,579,000 | $95,603,000 |
| General And Administrative Expense | $72,701,000 | $72,806,000 | $83,934,000 | $88,527,000 |
| Other Income Expense | - | $-7,205,000 | $-25,429,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-59,499,000 | $-159,492,000 | $-225,250,000 | $-200,191,000 |
| Net Interest Income | $-2,334,000 | $2,954,000 | $1,731,000 | $-182,000 |
| Interest Income | $9,444,000 | $14,534,000 | $15,531,000 | $4,056,000 |
| Normalized Income | $-59,499,000 | $-152,287,000 | $-199,821,000 | $-200,191,000 |
| Net Income From Continuing And Discontinued Operation | $-59,499,000 | $-159,492,000 | $-225,250,000 | $-200,191,000 |
| Total Operating Income As Reported | $-57,123,000 | $-162,549,000 | $-227,035,000 | $-200,186,000 |
| Net Income Common Stockholders | $-59,499,000 | $-159,492,000 | $-225,250,000 | $-200,191,000 |
| Net Income | $-59,499,000 | $-159,492,000 | $-225,250,000 | $-200,191,000 |
| Net Income Including Noncontrolling Interests | $-59,457,000 | $-159,595,000 | $-225,304,000 | $-200,368,000 |
| Net Income Continuous Operations | $-59,457,000 | $-159,595,000 | $-225,304,000 | $-200,368,000 |
| Pretax Income | $-59,457,000 | $-159,595,000 | $-225,304,000 | $-200,368,000 |
| Special Income Charges | $0 | $-7,205,000 | $-25,429,000 | $0 |
| Interest Income Non Operating | $9,444,000 | $14,534,000 | $15,531,000 | $4,056,000 |
| Operating Income | $-57,123,000 | $-155,344,000 | $-201,606,000 | $-200,186,000 |
| Depreciation Amortization Depletion Income Statement | $1,699,000 | $1,703,000 | $1,699,000 | $1,699,000 |
| Depreciation And Amortization In Income Statement | $1,699,000 | $1,703,000 | $1,699,000 | $1,699,000 |
| Amortization Of Intangibles Income Statement | $1,699,000 | $1,703,000 | $1,699,000 | $1,699,000 |
| Gross Profit | $205,617,000 | $106,877,000 | $94,723,000 | $127,399,000 |
| Per Share | ||||
| Diluted EPS | $-0.39 | $-1.08 | $-1.56 | $-1.40 |
| Basic EPS | $-0.39 | $-1.08 | $-1.56 | $-1.40 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-29,846,000 | $-121,554,000 | $-163,844,000 | $-175,210,000 |
| Total Unusual Items | $0 | $-7,205,000 | $-25,429,000 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $-7,205,000 | $-25,429,000 | $0 |
| Reconciled Depreciation | $17,833,000 | $19,256,000 | $22,231,000 | $20,920,000 |
| EBITDA (Bullshit earnings) | $-29,846,000 | $-128,759,000 | $-189,273,000 | $-175,210,000 |
| EBIT | $-47,679,000 | $-148,015,000 | $-211,504,000 | $-196,130,000 |
| Diluted Average Shares | $151,721,939 | $147,101,648 | $144,383,294 | $142,515,917 |
| Basic Average Shares | $151,721,939 | $147,101,648 | $144,383,294 | $142,515,917 |
| Diluted NI Availto Com Stockholders | $-59,499,000 | $-159,492,000 | $-225,250,000 | $-200,191,000 |
| Minority Interests | $-42,000 | $103,000 | $54,000 | $177,000 |
| Impairment Of Capital Assets | $0 | $7,205,000 | $25,429,000 | $0 |
| Amortization | $1,699,000 | $1,703,000 | $1,699,000 | $1,699,000 |
| Research And Development | $93,769,000 | $102,953,000 | $122,117,000 | $141,756,000 |
| Selling General And Administration | $167,272,000 | $157,565,000 | $172,513,000 | $184,130,000 |
| Other Gand A | $72,701,000 | $72,806,000 | $83,934,000 | $88,527,000 |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $98,095,000 | $80,312,000 | $184,299,000 | $338,366,000 |
| Total Assets | $512,736,000 | $539,376,000 | $661,134,000 | $856,617,000 |
| Total Non Current Assets | $212,551,000 | $255,624,000 | $250,946,000 | $294,471,000 |
| Other Non Current Assets | $3,896,000 | $5,184,000 | $6,523,000 | $4,462,000 |
| Investmentin Financial Assets | $13,234,000 | $33,660,000 | $0 | $0 |
| Goodwill And Other Intangible Assets | $120,698,000 | $122,397,000 | $124,100,000 | $125,799,000 |
| Other Intangible Assets | $1,726,000 | $3,425,000 | $5,128,000 | $6,827,000 |
| Current Assets | $300,185,000 | $283,752,000 | $410,188,000 | $562,146,000 |
| Other Current Assets | $13,020,000 | $11,287,000 | $11,370,000 | $9,440,000 |
| Inventory | $9,820,000 | $8,440,000 | $14,448,000 | $14,453,000 |
| Receivables | $50,365,000 | $41,731,000 | $37,969,000 | $40,057,000 |
| Accounts Receivable | $50,365,000 | $41,731,000 | $37,969,000 | $40,057,000 |
| Cash Cash Equivalents And Short Term Investments | $226,980,000 | $222,294,000 | $346,401,000 | $498,196,000 |
| Cash And Cash Equivalents | $70,495,000 | $47,920,000 | $65,064,000 | $90,030,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $79,148,000 | $89,387,000 | $98,772,000 | $108,002,000 |
| Long Term Debt And Capital Lease Obligation | $70,228,000 | $79,148,000 | $89,388,000 | $98,772,000 |
| Current Debt And Capital Lease Obligation | $8,920,000 | $10,239,000 | $9,384,000 | $9,230,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $287,735,000 | $336,891,000 | $352,856,000 | $392,519,000 |
| Total Non Current Liabilities Net Minority Interest | $197,820,000 | $238,838,000 | $264,841,000 | $282,731,000 |
| Other Non Current Liabilities | $126,586,000 | $132,434,000 | $130,660,000 | $125,360,000 |
| Non Current Deferred Liabilities | $1,006,000 | $27,256,000 | $44,793,000 | $58,599,000 |
| Current Liabilities | $89,915,000 | $98,053,000 | $88,015,000 | $109,788,000 |
| Other Current Liabilities | $4,642,000 | $865,000 | - | - |
| Current Deferred Liabilities | $45,194,000 | $55,689,000 | $48,630,000 | $64,115,000 |
| Payables And Accrued Expenses | $14,167,000 | $15,422,000 | $16,316,000 | $20,508,000 |
| Payables | $7,008,000 | $7,441,000 | $7,778,000 | $8,278,000 |
| Total Tax Payable | $541,000 | $176,000 | $59,000 | $194,000 |
| Accounts Payable | $6,467,000 | $7,265,000 | $7,719,000 | $8,084,000 |
| Equity | ||||
| Common Stock Equity | $218,793,000 | $202,709,000 | $308,399,000 | $464,165,000 |
| Total Equity Gross Minority Interest | $225,001,000 | $202,485,000 | $308,278,000 | $464,098,000 |
| Stockholders Equity | $218,793,000 | $202,709,000 | $308,399,000 | $464,165,000 |
| Gains Losses Not Affecting Retained Earnings | $253,000 | $166,000 | $215,000 | $-4,116,000 |
| Other Equity Adjustments | $253,000 | $166,000 | $215,000 | $-4,116,000 |
| Retained Earnings | $-1,363,323,000 | $-1,303,824,000 | $-1,144,332,000 | $-919,082,000 |
| Other | ||||
| Ordinary Shares Number | $153,779,418 | $147,773,744 | $145,082,271 | $143,105,002 |
| Share Issued | $153,779,418 | $147,773,744 | $145,082,271 | $143,105,002 |
| Tangible Book Value | $98,095,000 | $80,312,000 | $184,299,000 | $338,366,000 |
| Invested Capital | $218,793,000 | $202,709,000 | $308,399,000 | $464,165,000 |
| Working Capital | $210,270,000 | $185,699,000 | $322,173,000 | $452,358,000 |
| Capital Lease Obligations | $79,148,000 | $89,387,000 | $98,772,000 | $108,002,000 |
| Total Capitalization | $218,793,000 | $202,709,000 | $308,399,000 | $464,165,000 |
| Minority Interest | $6,208,000 | $-224,000 | $-121,000 | $-67,000 |
| Additional Paid In Capital | $1,581,848,000 | $1,506,353,000 | $1,452,502,000 | $1,387,349,000 |
| Capital Stock | $15,000 | $14,000 | $14,000 | $14,000 |
| Common Stock | $15,000 | $14,000 | $14,000 | $14,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $1,006,000 | $27,256,000 | $44,793,000 | $58,599,000 |
| Long Term Capital Lease Obligation | $70,228,000 | $79,148,000 | $89,388,000 | $98,772,000 |
| Current Deferred Revenue | $45,194,000 | $55,689,000 | $48,630,000 | $64,115,000 |
| Current Capital Lease Obligation | $8,920,000 | $10,239,000 | $9,384,000 | $9,230,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $16,992,000 | $15,838,000 | $13,685,000 | $15,935,000 |
| Current Accrued Expenses | $7,159,000 | $7,981,000 | $8,538,000 | $12,230,000 |
| Investments And Advances | $13,234,000 | $33,660,000 | $0 | $0 |
| Available For Sale Securities | $13,234,000 | $33,660,000 | - | - |
| Goodwill | $118,972,000 | $118,972,000 | $118,972,000 | $118,972,000 |
| Net PPE | $74,723,000 | $94,383,000 | $120,323,000 | $164,210,000 |
| Accumulated Depreciation | $-95,786,000 | $-87,817,000 | $-73,234,000 | $-54,350,000 |
| Gross PPE | $170,509,000 | $182,200,000 | $193,557,000 | $218,560,000 |
| Leases | $73,110,000 | $73,277,000 | $74,734,000 | $72,403,000 |
| Construction In Progress | $1,103,000 | $2,571,000 | $3,405,000 | $7,625,000 |
| Other Properties | $85,187,000 | $92,717,000 | $101,663,000 | $124,355,000 |
| Machinery Furniture Equipment | $11,109,000 | $13,635,000 | $13,755,000 | $14,177,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $156,485,000 | $174,374,000 | $281,337,000 | $408,166,000 |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-48,945,000 | $-98,876,000 | $-167,021,000 | $-200,294,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-45,986,000 | $-95,212,000 | $-156,324,000 | $-183,945,000 |
| Cash Flow From Continuing Operating Activities | $-45,986,000 | $-95,212,000 | $-156,324,000 | $-183,945,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,959,000 | $-3,664,000 | $-10,697,000 | $-16,349,000 |
| Investing Cash Flow | $37,950,000 | $77,792,000 | $129,647,000 | $2,905,000 |
| Cash Flow From Continuing Investing Activities | $37,950,000 | $77,792,000 | $129,647,000 | $2,905,000 |
| Financing Activities | ||||
| Financing Cash Flow | $30,403,000 | $241,000 | $2,245,000 | $132,265,000 |
| Cash Flow From Continuing Financing Activities | $30,403,000 | $241,000 | $2,245,000 | $132,265,000 |
| Net Other Financing Charges | $12,524,000 | - | - | $124,375,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Interest Paid Supplemental Data | $12,638,000 | $8,864,000 | $8,985,000 | $494,000 |
| End Cash Position | $73,184,000 | $50,817,000 | $67,996,000 | $92,428,000 |
| Beginning Cash Position | $50,817,000 | $67,996,000 | $92,428,000 | $141,203,000 |
| Changes In Cash | $22,367,000 | $-17,179,000 | $-24,432,000 | $-48,775,000 |
| Proceeds From Stock Option Exercised | $17,879,000 | $241,000 | $2,245,000 | $7,890,000 |
| Net Investment Purchase And Sale | $40,909,000 | $81,456,000 | $140,344,000 | $19,254,000 |
| Sale Of Investment | $222,623,000 | $325,713,000 | $569,902,000 | $298,032,000 |
| Purchase Of Investment | $-181,714,000 | $-244,257,000 | $-429,558,000 | $-278,778,000 |
| Net PPE Purchase And Sale | $-2,959,000 | $-3,664,000 | $-10,697,000 | $-16,349,000 |
| Purchase Of PPE | $-2,959,000 | $-3,664,000 | $-10,697,000 | $-16,349,000 |
| Change In Working Capital | $-57,767,000 | $-17,454,000 | $-46,183,000 | $-71,546,000 |
| Change In Other Working Capital | $-47,055,000 | $-19,836,000 | $-38,040,000 | $-60,377,000 |
| Change In Payables And Accrued Expense | $665,000 | $671,000 | $-5,407,000 | $7,111,000 |
| Change In Prepaid Assets | $-1,733,000 | $83,000 | $-1,930,000 | $3,551,000 |
| Change In Inventory | $-998,000 | $5,372,000 | $-2,838,000 | $817,000 |
| Change In Receivables | $-8,646,000 | $-3,744,000 | $2,032,000 | $-22,648,000 |
| Changes In Account Receivables | $-8,646,000 | $-3,744,000 | $2,032,000 | $-22,648,000 |
| Other Non Cash Items | $3,871,000 | $8,036,000 | $12,392,000 | $8,193,000 |
| Stock Based Compensation | $51,483,000 | $53,610,000 | $62,908,000 | $55,477,000 |
| Asset Impairment Charge | $563,000 | $9,143,000 | $26,816,000 | $0 |
| Amortization Of Securities | $-2,512,000 | $-8,208,000 | $-9,184,000 | $741,000 |
| Depreciation Amortization Depletion | $17,833,000 | $19,256,000 | $22,231,000 | $20,920,000 |
| Depreciation And Amortization | $17,833,000 | $19,256,000 | $22,231,000 | $20,920,000 |
| Amortization Cash Flow | $1,699,000 | $1,703,000 | $1,699,000 | $1,699,000 |
| Amortization Of Intangibles | $1,699,000 | $1,703,000 | $1,699,000 | $1,699,000 |
| Depreciation | $16,134,000 | $17,553,000 | $20,532,000 | $19,221,000 |
| Net Income From Continuing Operations | $-59,457,000 | $-159,595,000 | $-225,304,000 | $-200,368,000 |
| Provisionand Write Offof Assets | - | $1,938,000 | $1,387,000 | $2,638,000 |
| Issuance Of Debt | - | - | - | $124,375,000 |
| Net Issuance Payments Of Debt | - | - | - | $124,375,000 |
| Net Long Term Debt Issuance | - | - | - | $124,375,000 |
| Long Term Debt Issuance | - | - | - | $124,375,000 |
Fetched: 2026-06-02